Investment of $372.5 Million in Series D funding secured for advancing therapeutic solutions targeting the Central Nervous System.
MapLight Therapeutics, a biopharmaceutical company focused on developing novel treatments for brain disorders, has secured a significant investment to fuel its growth and advance its pipeline of potential medicines. The company announced a $372.5 million Series D financing, co-led by Forbion and Goldman Sachs Alternatives.
The investor syndicate for this round also includes Sanofi, T. Rowe Price, Avego BioScience, Novo Holdings, 5AM Ventures, Blue Owl, and existing investors. Notable individuals joining the MapLight Therapeutics board include Josh Richardson, M.D., Managing Director, Life Sciences at Goldman Sachs Alternatives, and Nanna Lüneborg, Ph.D., M.B.A., a partner at Forbion.
Goldman Sachs Alternatives views ML-007C-MA, an oral combination of M1/M4 muscarinic agonist ML-007 with a peripherally acting anticholinergic, as a potential best-in-class treatment for M1/M4 muscarinic receptors. The goal of ML-007C-MA is to activate CNS receptors and reduce side effects, making it well-positioned to address the substantial unmet medical need in schizophrenia, Alzheimer's disease, and other CNS indications.
Josh Richardson, M.D., expressed his excitement about partnering with the team at MapLight to fuel innovations in the CNS space. Nanna Lüneborg, who will join the Board of MapLight Therapeutics, shared the investor syndicate's optimism about the potential of ML-007C-MA in the CNS space.
Christopher Kroeger, M.D., M.B.A., the Chief Executive Officer and Founder of MapLight Therapeutics, stated that the caliber of the new investor group and the continued strong support from existing shareholders is a testament to the company's compelling vision and strategy.
The funds from this financing will be primarily used to advance ML-007C-MA through Phase 2 trials for schizophrenia and Alzheimer's, explore other indications, and support pipeline programs. Additionally, the funding will support research activities, clinical trials, manufacturing scale-up, and expanding the overall therapeutic pipeline to bring multiple candidates closer to potential commercialization.
This investment is seen as a validation of MapLight's differentiated product pipeline, dedicated team, and commitment to advancing new medicines for brain disorders. With the new funding and the addition of renowned investors and board members, MapLight Therapeutics is poised to make significant strides in the development of groundbreaking treatments for brain disorders.
Science and health-and-wellness intersect as MapLight Therapeutics, a biopharmaceutical company focused on developing novel treatments for brain disorders, secures a significant investment to further its research in mental health. The potential medicine, ML-007C-MA, is viewed as a best-in-class treatment for M1/M4 muscarinic receptors, showing promise in addressing the substantial unmet medical need in schizophrenia, Alzheimer's disease, and other CNS indications. The investment looking to advance ML-007C-MA through various therapies and treatments, mainly through Phase 2 trials, reinforces the company's dedication in the field of mental health.
